Kiniksa Pharmaceuticals International, plc (KNSA)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$190.0M
Cash & Equivalents
$50.2M
Quarterly Burn Rate
$3,988M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07010159 Phase 2/3 Study of KPL-387 in Recurrent Pericarditis PHASE3 Recruiting 165
NCT07288216 Transition to KPL-387 Monotherapy Dosing & Administration Study PHASE2 Recruiting 80

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for KNSA.

SEC EDGAR Filings

All SEC filings for Kiniksa Pharmaceuticals International, plc on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.